Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL? - Top-Institutions - MDSpire

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?

  • By

  • Seung Hwan Lee

  • Mun Su Chung

  • Kyung Kgi Park

  • Chan Dong Yom

  • Dae Hoon Lee

  • Byung Ha Chung

  • July 16, 2011

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urologic Oncology
    • Nuclear Medicine
    • Radiology

  • #2

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Urology
    • Oncology
    • Radiology

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Urologic Oncology
    • Nuclear Medicine
    • Radiology

  • #4

    National Cancer Center Hospital
    National Cancer Center Hospital

    Tokyo, Tokyo

    Key Differentiators

    • Urologic Oncology
    • Nuclear Medicine
    • Epidemiology

  • #5

    Seoul National University Hospital
    Seoul National University Hospital

    Seoul, Seoul

    Key Differentiators

    • Urology
    • Oncology
    • Nuclear Medicine

Original Source(s)

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?

  • by Seung Hwan Lee, Mun Su Chung, Kyung Kgi Park, Chan Dong Yom, Dae Hoon Lee, Byung Ha Chung

  • July 16, 2011

Related Content

Sharper Imaging, Smarter Tools: Inside the MonacoPro

With its combination of UWF imaging, OCT integration, and intelligent review tools, the MonacoPro represents the next step in comprehensive retinal evaluation. By improving image quality, enhancing diagnostic confidence, and streamlining workflow, the system supports clinicians in delivering more efficient, informed, and patient-centered care.

Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions

Early experience with targeted and combination biopsies in prostate cancer work-up in Denmark from 2012 to 2016